Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Atopic dermatitis drug risks

Executive Summary

The risks of atopic dermatitis drugs will be the topic of an Oct. 29-30 meeting of the Pediatric Subcommittee of FDA's Anti-Infective Drugs Advisory Committee. On Oct. 29, the committee will discuss the risks of hypothalamic-pituitary axis suppression in children being treated for atopic dermatitis. The committee will also hear reports on adverse events with Pfizer's Zyrtec and Accupril; Merck's Cozaar; AstraZeneca's Nolvadex, Orphan Medical's Busulfex and Bristol-Myers Squibb's Serzone. On Oct. 30, the committee will discuss long-term monitoring of cancer recurrence in atopic dermatitis patients who are being treated with immunosuppressants. The meeting will be held at the Hilton in Gaithersburg, Md. beginning at 8 a.m...

You may also be interested in...



Optibac Launches Natural Children’s Probiotic Immunity Supplement In Sustainable Pack

The UK's Optibac responds to sustainability and naturals trends with an all-in-one immunity and gut health food supplement especially designed for children.

India To Scrap Intellectual Property Appellate Board: Should Pharma Worry?

Legal experts tell the Pink Sheet why India’s plans to abolish the Intellectual Property Appellate Board and shift its powers to courts may be problematic for stakeholders, including those pursuing infringement charges. The transition could mean a significant burden on courts both in terms of capability and capacity, and IPR cases will now conflate into all other pending commercial matters, some experts said, though others cheered the proposed change.

QUOTED. 5 March 2021. Dedi Gilad.

Tyto Care’s remote monitoring and telehealth platform has seen rising demand since the start of the pandemic and the company continues to expand. This week, it announced it raised $50m in a series D financing round. See what Dedi Gilad, CEO of Tyto Care, said about it here.

UsernamePublicRestriction

Register

OM017181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel